Cadrenal Therapeutics, Inc. Common Stock
CVKDStock
$2.33−80.64%52W
Market Cap$6.94M
P/E—
Div yield—
Beta1.76
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-73.76%
Price vs S&P 500 (4W)-26.93%
VGM Score8.85
Market Capitalization$6.94M
Earnings Surprise History
Q1 26-1.04est. -1.65
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.14
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CVKDCadrenal Therapeutics, Inc. Common Stock | — | — | F | $2.33 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Cadrenal Therapeutics is developing tecarfarin, a late-stage novel oral anticoagulant designed to address unmet needs in treating rare cardiovascular conditions requiring chronic anticoagulation therapy. The reversible blood thinner is intended to prevent heart attacks, strokes, and clot-related mortality in patients with specific cardiovascular indications.